Immune Design Corp.
GLA Monotherapy for use in Cancer Treatment
Last updated:
Abstract:
The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.
Status:
Application
Type:
Utility
Filling date:
20 May 2019
Issue date:
5 Sep 2019